A New Immunotherapy/Immunoprevention for Ovarian Cancer

Inventors

Vincent Tuohy, PhD
Justin Johnson
Ritiki Jaini, PhD

Questions?

Contact Innovation Manager

Tony Giordano, PhD

What is it? What does it do?

Anti-Mullerian hormone receptor II (AMHR2) is an ovarian-specific differentiation protein.  In normal adult females, AMHR2 expression is confined to ovarian granulosa cells with lower expression found in a handful of other tissues however, unlike ovarian expression, in each of these tissues the AMHR2 extracellular binding domain is absent, thus this ovary-specific extracellular domain is being targeted.  Expression of AMHR2 declines dramatically in post-menopausal human ovaries but is found in approximately 90% of primary epithelial ovarian cancers (EOCs) and >50% of other ovarian cancers, making this an attractive target candidate for immunotherapy/immunoprevention in post-menopausal women.

Why is it better?

  • AMHR2 extracellular domain is expressed normally only in ovarian tissue but in 90% of all EOCs and 50% of other ovarian cancers.
  • Recurrence rate with current standard of care approaches to treating ovarian cancer results in a 5 year survival rate of just under 50%.
  • Given the lack of appreciable expression of the AMHR2 extracellular domain in post-menopausal women, side effects should be negligible.
  • AMHR2 can be combined with other checkpoint inhibitors, such as PD-L1 to enhance tumor inhibiting effects.

What is its current status?

Animal studies have been completed demonstrating the ability of AMHR2 vaccination to significantly inhibited growth of both autochthonous and transplantable ovarian tumors and dramatically increase overall survival.  In addition, combining AMHR2 with a PD-L1 inhibitor enhanced the tumor inhibiting effects.   Vaccination of mice was shown to be very safe, only transient oophoritis was observed with no effect on fertility.


Get in Touch With Us